drugsafetypng | ApconiX

Making Safety Part of Drug Design

ApconiX has organised a free to attend, one day symposium on drug discovery safety at Magdalene College, Cambridge on the 12th of October. Speakers from GSK, SEDA Pharmaceutical Development Services, AstraZeneca, MSD, ApconiX and Newcells Biotech will deliver a broad scope of thought-provoking presentations.

The discovery and development of novel medicines with improved safety profiles are vital if we are to advance and expand treatment options available and improve outcomes for patients. Currently, safety issues in clinical development remain a major challenge to our industry and the time to reduce or eliminate potential safety liabilities is in the discovery phase while projects still have chemical choice.

This one day meeting will bring together experts in the field to consider different aspects of making safety an intrinsic part of drug design from target and chemical evaluation through to regulatory strategy.  We are planning a full programme of short talks. The day will run from 9am to 5pm with lunch and refreshments provided throughout the day. The meeting will be highly relevant for pharma and biotech industry, academics and government scientists in the drug discovery and development field.

Invitations to register for the symposium will be sent out later in August.  We look forward to welcoming you to this event.

One Day Symposium Programme

Cripps Court
Magdalene College
1-3 Chesterton Road

October 12th 2023

Click here to download the programme

(subject to change)

Time Title Speaker
9-9:45 Arrival and Registration with coffee and pastries


Professor Ruth Roberts, ApconiX

Opening Keynote
10-10:30 Reducing the Risk of Mitochondrially Active Compounds in Medicines Development Dr Jon Lyon – Director of Preclinical Toxicity and Mitochondrial Network Lead, GSK
Morning Session
10:30-11 Assessing Cardiac Ion Channel Activity in the Drug Discovery Cascade Dr Mike Morton, ApconiX
11-11:30 Making formulation part of drug design: case studies Dr Linette Ruston, Director, ADME and Modelling Sciences, SEDA Pharmaceuticals
11:30-12 The role of Target Safety Assessments (TSAs) in derisking drug projects Dr James Sidaway, ApconiX
12-13 Lunch Break
Afternoon Session
13-13:30 Interfacing DMPK and Safety in Drug Design: Concentration effect relationships Dr Kevin Beaumont, Senior Director, DMPK, AstraZeneca
13:30-14 Developing an ion channel seizure panel Dr Kim Rockley, ApconiX
14-14:30 Designing out secondary pharmacology hits Dr Mark Anderton, Senior Principal Scientist, MSD
14:30-15 Coffee/Tea
15-15:30 State-of-the-art cellular models in de-risking drug design Dr Colin Brown, Chief Innovation Officer, Newcells Biotech
15:30-16 Making safety part of drug design – a regulatory perspective Dr David Jones, ApconiX
16:00 Panel discussion Dr David Jones
Dr Richard Knight
Dr Anthony Holmes
Dr Muireann Coen
16:30 Close

Cripps Court is located just around the corner from the main porters lodge of Magdalene College on Chesterton Road in Cambridge City centre.